Irritable Bowel Syndrome (IBS) -Epidemiology Forecast to 2028

"Irritable Bowel Syndrome (IBS) - Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Irritable Bowel Syndrome (IBS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2016-2028

Irritable Bowel Syndrome (IBS) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Irritable Bowel Syndrome (IBS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders views are also taken into account to provide a deep understanding of the Irritable Bowel Syndrome (IBS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Irritable Bowel Syndrome (IBS) scenario.

Irritable Bowel Syndrome (IBS) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Irritable Bowel Syndrome (IBS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
The report covers detailed overview of Irritable Bowel Syndrome (IBS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Irritable Bowel Syndrome (IBS) Report assesses the disease risk and burden and highlights the unmet needs
It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
10 Year Forecast
7MM Coverage
Total Cases in Irritable Bowel Syndrome (IBS)

Key assessments
Patient Segmentation in Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) Risk & Burden
Factors driving growth in a specific Irritable Bowel Syndrome (IBS) patient population
1. Report Introduction
2. Irritable Bowel Syndrome (IBS) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Irritable Bowel Syndrome (IBS) in 2016
2.2. Patient Share Distribution of Irritable Bowel Syndrome (IBS) in 2028
3. Disease Background and Overview: Irritable Bowel Syndrome (IBS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Irritable Bowel Syndrome (IBS) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Irritable Bowel Syndrome (IBS) in 7MM By Countries
5. Epidemiology of Irritable Bowel Syndrome (IBS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.1.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) *
5.1.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.1.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.4.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.4.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.4.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.5.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.5.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.5.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.6.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.6.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.6.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.7.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.7.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.7.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.8.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.8.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.8.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
5.9.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)*
5.9.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)*
5.9.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
6. Unmet Needs of the Irritable Bowel Syndrome (IBS)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List Of Tables

Table 1: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)


List Of Figures

Figure 1: Total Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the IrriFigure Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the IrriFigure Bowel Syndrome (IBS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the IrriFigure Bowel Syndrome (IBS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the IrriFigure Bowel Syndrome (IBS) in Japan (2016-2028)


Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Drugs In Development, 2021, provides an overview of

USD 2000 View Report

Irritable Bowel Syndrome - Pipeline Review, H2 2020

Irritable Bowel Syndrome - Pipeline Review, H2 2020 latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2020, provides an overview of the Irritable Bowel

USD 2000 View Report

Global Irritable Bowel Syndrome Market Outlook

Irritable bowel syndrome is one of the foremost common disorders that affect the massive intestine. It causes cramping, abdominal pain, bloating, diarrhea, gas, and constipation. The disease is additionally referred

USD 3950 View Report

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Drugs In Development, 2021, provides an overview of

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available